R&D Vision and Strategy

At SHIONOGI, we believe that to grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improved healthcare is impossible without the constant pursuit of innovation contributing to the resolution of social issues. To that end, we seek to continue creating new drugs, by investing appropriate sums in R&D and maintaining small molecule drug discovery as a key strength and deepening collaboration with all manner of partners including the IT industry, in order to expand into new modalities and acquire entirely new technologies. If we are to meet the needs of both our customers and society as a whole and become a source of new value in the healthcare field, we think it essential that SHIONOGI remain committed to innovation, particularly as it applies to R&D.

"Creating the future of healthcare with a new platform" is what the SHIONOGI Group wants to achieve by 2030. To achieve this, our research and development has set a vision of "thinking outside the box to meet important healthcare needs in society and create innovations that go beyond medical drugs" and is working toward that vision every day.

•In order to provide the healthcare solutions that our customers need, it is essential to make decisions that combine quality and speed, deploy resources quickly based on priorities, and collaborate seamlessly across organizations and functions. We have established an R&D structure to achieve these goals.

•The Drug Discovery Research Division prioritizes providing optimal diagnostic and treatment opportunities that meet unmet medical needs, and will specialize in research to create healthcare solutions while leveraging the strengths of small molecule drug discovery.

The Pharmaceutical Technology Research Division uses its technological capabilities to play an important role in making pharmaceutical seeds easier to use, less expensive, and more easily delivered to medical settings.

 As vaccines are a unique and specialized business, we have newly established the Vaccine Business Division, which can handle everything from research to supply.

SHIONOGI has a long history of small molecule drug discovery, but there are some diseases that cannot be addressed by small molecules alone. In order to meet diverse unmet medical needs, we will strengthen various capabilities, such as vaccines, antibodies, peptides, and nucleic acids, as well as new drug delivery technologies and digital approaches such as conjugate drugs and digital therapeutics, by utilizing internal and external networks. By utilizing AI/IT and promoting automation in research sites to innovate the new drug discovery process, we will create an environment where we can provide the healthcare solutions you need more quickly.